Choi, Michael Y.
Widhopf, George F. II
Ghia, Emanuela M.
Kidwell, Reilly L.
Hasan, Md Kamrul
Yu, Jian
Rassenti, Laura Z.
Chen, Liguang
Chen, Yun
Pittman, Emily
Pu, Minya
Messer, Karen
Prussak, Charles E.
Castro, Januario E.
Jamieson, Catriona
Kipps, Thomas J.
Funding for this research was provided by:
California Institute of Regenerative Medicine (CIRM) (DR3-06924)
CIRM Alpha Stem Cell clinic (CIRM AC1-07764)
Moores Cancer Center Specialized Cancer Center Support Grant (NIH NCI 2P30CA023100-28)
UC San Diego Foundation Blood Cancer Research Fund (BCRF; F-3133)
Koman Family Foundation (7005-14)
Leukemia and Lymphoma Society (5P01CA081534-14)
NIH (P30CA023100)
This article is maintained by: Elsevier
Article Title: Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
Journal Title: Cell Stem Cell
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.stem.2018.05.018
Content Type: article
Copyright: © 2018 Published by Elsevier Inc.